Actualización para el médico práctico | 30 OCT 17

Polimialgia reumática

Una enfermedad inflamatoria que predomina en los adultos mayores y suele asociarse a la arteritis de células gigantes
Autor/a: Miguel A González-Gay, Eric L Matteson, Santos Castañeda Polymyalgia rheumatica. Lancet 2017; 390: 1700–12,
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

1 Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347: 261–71.

2 Hunder GG. The early history of giant cell arteritis and polymyalgia rheumatica: first descriptions to 1970. Mayo Clin Proc 2006; 81: 1071–83. 1 Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347: 261–71.

2 Hunder GG. The early history of giant cell arteritis and polymyalgia rheumatica: first descriptions to 1970. Mayo Clin Proc 2006; 81: 1071–83. 3 Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009; 61: 1454–61.

4 Raheel S, Shbeeb I, Crowson CS, Matteson EL. Epidemiology of polymyalgia rheumatica 2000–2014 and examination of incidence and survival trends over 45 years: a population based study. Arthritis Care Res 2016; published online Oct 21. DOI:10.1002/

acr.23132.5 Boesen P, Sorensen SF. Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county: a prospective

investigation, 1982–1985. Arthritis Rheum 1987; 30: 294–99.

6 Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 1996; 23: 112–19.

7 Schaufelberger C, Bengtsson BA, Andersson R. Epidemiology and mortality in 220 patients with polymyalgia rheumatica. Br J Rheumatol 1995; 34: 261–64.

8 Doran MF, Crowson CS, O’Fallon WM, Hunder GG, Gabriel SE. Trends in the incidence of polymyalgia rheumatic over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol 2002;29: 1694–97.

9 Salvarani C, Macchioni P, Zizzi F, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991; 34: 351–56.

10 Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M, Dababneh A, Hajeer A, Ollier WE. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 1999; 26: 1326–32.

11 Crowson CS, Matteson EL. Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatic. Semin Arthritis Rheum 2017; published online April 7. DOI:10.1016/j.semarthrit.2017.04.001.

12 Yates M, Graham K, Watts RA, MacGregor AJ. The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population. BMC Musculoskelet Disord 2016; 17: 285.

13 Carmona FD, Mackie SL, Martin JE, et al. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. Am J Hum Genet 2015; 96: 565–80.

14 Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WE. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 2003; 33: 38–48.

15 Boiardi L, Casali B, Farnetti E, et al. Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. J Rheumatol 2006; 33: 703–08.

16 Gonzalez-Gay MA, Hajeer AH, Dababneh A, et al. IL-6 promoter polymorphism at position-174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cellarteritis. Clin Exp Rheumatol 2002; 20: 179–84.

17 Peris P. Polymyalgia rheumatica is not seasonal in pattern and is unrelated to parvovirus b19 infection. J Rheumatol 2003; 30: 2624–26.

18 Rhee RL, Grayson PC, Merkel PA, Tomasson G. Infections and the risk of incident giant cell arteritis: a population-based, case-control study. Ann Rheum Dis 2017; 76: 1031–35.

19 Meliconi R, Pulsatelli L, Uguccioni M, et al. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. Arthritis Rheum 1996; 39: 1199–207.

20 Salvarani C, Cantini F, Olivieri I, Hunder GS. Polymyalgia rheumatica: a disorder of extraarticular synovial structures? J Rheumatol 1999; 26: 517–21.

21 Salvarani C, Cantini F, Olivieri I, et al. Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med 1997; 127: 27–31.

22 Cantini F, Salvarani C, Olivieri I, et al. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. J Rheumatol 2001; 28: 1049–55.

23 Cantini F, Niccoli L, Nannini C, et al. Inflammatory changes of hip synovial structures in polymyalgia rheumatica. Clin Exp Rheumatol2005; 23: 462–68.

24 Salvarani C, Barozzi L, Cantini F, et al. Cervical interspinous bursitis in active polymyalgia rheumatica. Ann Rheum Dis 2008; 67: 758–61.

25 Salvarani C, Barozzi L, Boiardi L, et al. Lumbar interspinous bursitis in active polymyalgia rheumatica. Clin Exp Rheumatol 2013; 31: 526–31.

26 Gonzalez-Gay MA. The clinical implication of cervical interspinous bursitis in the diagnosis of polymyalgia rheumatica. Ann Rheum Dis 2008; 67: 733–34.

27 Kreiner F, Langberg H, Galbo H. Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica. Arthritis Rheum 2010; 62: 3768–75.

28 Gonzalez-Gay MA, Pina T. Giant cell arteritis and polymyalgia rheumatica: an update. Curr Rheumatol Rep 2015; 17: 6.

29 Samson M, Audia S, Fraszczak J, et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum 2012;64: 3788–98.

30 van der Geest KS, Abdulahad WH, Chalan P, et al. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol 2014; 66: 1927–38.

31 Kermani TA, Warrington KJ. Polymyalgia rheumatica. Lancet 2013; 381: 63–72.

32 Masson C, Gonzalez-Gay MA. Polymyalgia rheumatica and giant cell arteritis. In: Bijlsma JWJ, Hachulla E, eds. EULAR textbook on rheumatic diseases, 2nd edn. London: BMJ Publishing Group, 2015:754–78.

33 Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M. Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. J Rheumatol 1998; 25: 1750–55.

34 Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 1982; 97: 672–80.

35 Gonzalez-Gay MA, Garcia-Porrua C, Amor-Dorado JC, Llorca J. Fever in biopsy-proven giant cell arteritis: clinical implications in a defined population. Arthritis Rheum 2004; 51: 652–55.

36 Gonzalez-Gay MA, Garcia-Porrua C. Polymyalgia rheumatic vs rheumatoid arthritis in the elderly. Arch Intern Med 1997; 157: 2016.

37 Pease CT, Haugeberg G, Montague B, et al. Polymyalgia rheumatic can be distinguished from late onset rheumatoid arthritis at baseline: results of a 5-yr prospective study. Rheumatology 2009; 48: 123–27.

38 Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 2012; 64: 943–54.

39 Salvarani C, Cantini F, Macchioni PL, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica. Arthritis Rheum 1998;41: 1221–26.

40 Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, Hunder GG. Diagnostic approach in a patient presenting with polymyalgia. Clin Exp Rheumatol 1999; 17: 276–78.

41 Salvarani C, Gabriel S, Hunder GG. Distal extremity swelling with pitting edema in polymyalgia rheumatica. Report of nineteen cases. Arthritis Rheum 1996; 39: 73–80.

42 McCarty DJ, O’Duffy JD, Pearson L, Hunter JB. Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA 1985; 254: 2763–67.

43 Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979; 38: 434–39.

44 Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984; 13: 322–28.

45 Jones JG, Hazleman BL. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis 1981; 40: 1–5.

46 Gonzalez-Gay MA, Rodriguez-Valverde V, Blanco R, et al. Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate. A more benign syndrome. Arch Intern Med 1997; 157: 317–20.

47 Proven A, Gabriel SE, O’Fallon WM, Hunder GG. Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis. J Rheumatol 1999; 26: 1333–37.

48 Salvarani C, Cantini F, Boiardi L, Hunder GG. Laboratory investigations useful in giant cell arteritis and Takayasu’s arteritis. Clin Exp Rheumatol 2003; 21 (suppl 32): S23–28.

49 Pipitone N, Salvarani C. Update on polymyalgia rheumatica. Eur J Intern Med 2013; 24: 583–89.

50 van der Geest KS, Abdulahad WH, Rutgers A, et al. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology 2015; 54: 1397–402.

51 Weyand CM, Goronzy JJ. Clinical practice. Giant cell arteritis and polymyalgia rheumatica. N Engl J Med 2014; 371: 50–57.

52 Baerlecken NT, Linnemann A, Gross WL, et al. Association of ferritin autoantibodies with giant cellarteritis/polymyalgia rheumatica. Ann Rheum Dis 2012; 71: 943–47.

53 Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ, et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine 2007; 86: 61–68.

54 Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum 2004; 33: 289–93.

55 Dababneh A, Gonzalez-Gay MA, Garcia-Porrua C, Hajeer A, Thomson W, Ollier W. Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. J Rheumatol 1998; 25: 2140–45.

56 Mattey DL, Hajeer AH, Dababneh A, et al. Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms. Arthritis Rheum 2000;43: 1749–55.

57 Gonzalez-Gay MA, Garcia-Porrua C, Amor-Dorado JC, Llorca J. Giant cell arteritis without clinically evident vascular involvement in a defined population. Arthritis Rheum 2004; 51: 274–77.

58 Nesher G, Breuer GS. Giant cell arteritis and polymyalgia rheumatica: 2016 update. Rambam Maimonides Med J 2016; 7: e0035.

59 Martinez-Rodriguez I, Martinez-Amador N, Banzo I, et al. Assessment of aortitis by semiquantitative analysis of 180-min 18F-FDG PET/CT acquisition images. Eur J Nucl Med Mol Imaging 2014; 41: 2319–24.

60 Lavado-Perez C, Martinez-Rodriguez I, Martinez-Amador N, et al. 18F-FDG PET/CT for the detection of large vessel vasculitis in patients with polymyalgia rheumatica. Rev Esp Med Nucl Imagen Mol 2015; 34: 275–81.

61 Loricera J, Blanco R, Hernandez JL, et al. Use of positron emission tomography (PET) for the diagnosis of large-vessel vasculitis. Rev Esp Med Nucl Imagen Mol 2015; 34: 372–77.

62 Loricera J, Blanco R, Hernandez JL, et al. Non-infectious aortitis: a report of 32 cases from a single tertiary centre in a 4-year period and literature review. Clin Exp Rheumatol 2015; 33 (suppl 89): S19–31.

63 Gonzalez-Gay MA, Garcia-Porrua C, Salvarani C, OlivieriI, Hunder GG. The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol 2000;27: 2179–84.

64 Owen CE, Buchanan RR, Hoi A. Recent advances in polymyalgia rheumatica. Intern Med J 2015; 45: 1102–08.

65 Healey LA. Polymyalgia rheumatica and seronegative rheumatoid arthritis may be the same entity. J Rheumatol 1992; 19: 270–72.

66 Bahlas S, Ramos-Remus C, Davis P. Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis. J Rheumatol 1998;25: 99–104.

67 Ceccato F, Roverano S, Barrionuevo A, Rillo O, Paira S. The role of anticyclic citrullinated peptide antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Clin Rheumatol 2006; 25: 854–57.

68 Pease CT, Haugeberg G, Morgan AW, Montague B, Hensor EM, Bhakta BB. Diagnosing late onset rheumatoid arthritis, polymyalgia rheumatica, and temporal arteritis in patients presenting with polymyalgic symptoms. A prospective long term evaluation. J Rheumatol 2005; 32: 1043–46.

69 Wakura D, Kotani T, Takeuchi T, et al. Differentiation between polymyalgia rheumatica (PMR) and elderly-onset rheumatoid arthritis using 18F-fluorodeoxyglucose positron emission tomography/computed tomography: is enthesitis a new pathological lesion in PMR? PLoS One 2016; 11: e0158509.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024